

# HYLORIS PHARMACEUTICALS SA

ISIN: BE0974363955 WKN: - Asset Class: **Stock**

## Company

2024/08/15 17:35:15



Price

**6.64** EUR

Difference ▲ 0.30%(0.02)



## Contact Details

HYLORIS PHARMACEUTICALS  
SA

Tel: +32-4-346-02-07

--

Fax: +

Boulevard Patience et Beaujonc  
N°3/1

Web:

<http://www.hyloris.com>

4000 Liege

E-mail:

[contact@hyloris.com](mailto:contact@hyloris.com)

## Company Profile

Hyloris Pharmaceuticals SA engages in the development and reformulating of pharmaceutical products. It offers commercial-stage products, Sotalol IV for the treatment of atrial fibrillation; and Maxigesic IV, a novel, dual modeof-action non-opioid analgesic for the treatment of post-operative pain. The company was founded by Stijn van Rompay and Thomas Jacobsen in 2012 and is headquartered in Liege, Belgium.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	35,308,000		50,801,000		53,959,000	
<b>Common stock capital</b>		140,000		140,000		129,000
<b>Fixed assets</b>	12,373,000		11,063,000		9,485,000	
<b>Equity capital of a company</b>		39,069,000		55,045,000		48,057,000
<b>Cash and cash equivalents</b>	30,406,000		43,457,000		50,012,000	
<b>Accrued liabilities</b>		0		0		0
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		6,759,000		5,772,000		14,978,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		1,853,000		1,047,000		409,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		0		0		0
<b>Total assets</b>	47,681,000	47,681,000	61,864,000	61,864,000	63,444,000	63,444,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	IFRS	IFRS	IFRS
<b>Employees</b>	41	37	-
<b>Equity ratio</b>	81.94%	88.98%	75.75%
<b>Debt-equity ratio</b>	22.04%	12.39%	32.02%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	3.75%	2.84%	0.78%

# HYLORIS PHARMACEUTICALS SA

ISIN: BE0974363955 WKN: - Asset Class: **Stock**

## Income statement

	2023	2022	2021
<b>Turnover</b>	2,087,000	2,951,000	3,096,000
<b>Net income</b>	-15,380,000	-10,770,000	-11,579,000
<b>EBIT</b>	-16,595,000	-10,702,000	-10,927,000
<b>Operating income before taxes</b>	-15,826,000	-10,951,000	-11,478,000
<b>Cash Flow</b>	-12,182,000	-15,031,000	-11,250,000
<b>Net interest income</b>	769,000	-249,000	-551,000
<b>Research and development expenses</b>	14,421,000	10,151,000	5,033,000
<b>Income taxes</b>	-593,000	-311,000	-90,000
<b>Result from investments in subsidiaries, associates and other</b>	-147,000	-130,000	-191,000
<b>Revenues per employee</b>	50,902	79,757	-

## Board of Directors

Stefan Yee	Chairman of Supervisory Board
Carolyn Myers	Member of Supervisory Board
Chris Buyse	Member of Supervisory Board
James Gale	Member of Supervisory Board
Leon van Rompay	Member of Supervisory Board
Marc Foidart	Member of Supervisory Board
Thomas Jacobsen	Member of Supervisory Board

## Members of Management Board

Stijn van Rompay	Chairman of Managing Board
Dietmar Aichhorn	Member of Executive Committee
Jean-Luc Vandebroek	Member of Executive Committee
Koenraad van der Elst	Member of Executive Committee
Thomas Jacobsen	Member of Executive Committee